LD-2 disclosure · 4th Quarter - Report
PFIZER INC.
via PFIZER INC.
Client
- Name
- PFIZER INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- PFIZER INC.
- Description
- Biopharmaceuticals
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
3 issuesHealth Issues
Vaccine Policy, Coverage and Access Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule Drug Pricing PBM Reform H.R. 4581 - 340B PATIENTS Act of 2025 H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026 S. 1053 - FIGHT China Act Cancer Research Centers for Disease Control and Prevention (CDC) Policies
LobbyistsEMILY MUELLER · FRANCISCO CARRILLO · MATTHEW STROIA · ms JENNIFER SWENSON WALTON · mrs ANGELA BOOTHE WILES
TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP) · Health & Human Services, Dept of (HHS) · Centers For Disease Control & Prevention (CDC) · Food & Drug Administration (FDA) · Natl Institutes of Health (NIH)
Medicare/Medicaid
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 5256 - 340B Access ACT Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule H.R. 4581 - 340B PATIENTS Act of 2025 340B Reform 340B HHS Pilot Program Model Insurance Coverage of Prescription Drugs Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage PBM Reform P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid
LobbyistsEMILY MUELLER · FRANCISCO CARRILLO · MATTHEW STROIA · ms JENNIFER SWENSON WALTON · mrs ANGELA BOOTHE WILES
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS)
